APLS Oct 2024 40.000 put
| Previous close | 2.45 |
| Open | 6.20 |
| Bid | 4.70 |
| Ask | 5.70 |
| Strike | 40.00 |
| Expiry date | 2024-10-18 |
| Day's range | 6.10 - 6.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
ZacksWill Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireApellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA’s expert groupsApellis anticipates a CHMP opinion no later than July 2024 WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the European Medicines Agency (EMA) has reset the review of the marketing authorization application (MAA) for intravitreal pegcetacoplan for geographic atrophy to the last phase of the init
- GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of t
